- Home
- OPK vs XNCR Comparison
OPK vs XNCR Comparison
Compare OPK & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OPK | XNCR |
|---|---|---|
| Founded | 2006 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 921.2M | 881.9M |
| IPO Year | 2011 | 2013 |
Fundamental Metrics
Financial Performance| Metric | OPK | XNCR |
|---|---|---|
| Price | $1.14 | $12.78 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $1.60 | ★ $22.33 |
| AVG Volume (30 Days) | ★ 2.1M | 699.2K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $606,879,000.00 | $125,576,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.24 | $4.80 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $0.98 | $6.92 |
| 52 Week High | $1.60 | $18.69 |
Technical Indicators
Market Signals| Indicator | OPK | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 43.67 | 52.47 |
| Support Level | $1.12 | $12.19 |
| Resistance Level | $1.25 | $13.10 |
| Average True Range (ATR) | 0.04 | 0.82 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 55.85 | 56.81 |
Price Performance
Historical ComparisonAbout OPK OPKO Health Inc.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.